Evidence map›Paper›PMID 40672753›Full record

ArticleFrontiers in oncology2025

Expression of Insulin-like growth factor 2 mRNA-binding protein 3 and its diagnostic value in breast cancer.

Chao-Qun Wang, Jun-Kang Shao, Yan Wang, Shi-Ping Lu, Li-Jing Jiang, Zhi-Qun Du, Bi-Fei Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chao-Qun WangDepartment of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
Jun-Kang ShaoDepartment of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
Yan WangDepartment of Medical Oncology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
Shi-Ping LuDepartment of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
Li-Jing JiangDepartment of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
Zhi-Qun DuDepartment of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
Bi-Fei HuangDepartment of Pathology, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is currently no established systematic explanation of the clinical application and diagnostic value of insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) in breast cancer. This study utilized immunohistochemistry (IHC) to assess the expression of the IGF2BP3 protein in 299 cases of breast cancer tissues, with the aim of investigating the clinical and diagnostic significance of IGF2BP3 in breast cancer. Our results showed that the positivity rate of IGF2BP3 in breast cancer tissues was 11.4% (34/299), significantly higher than that in normal breast tissues (0.0%, 0/60) (

Indexed as

breast cancerIGF2BP3immunohistochemistryinsulin-like growth factor 2 mRNA-binding protein 3prognosis

Identifiers

PMID40672753
PMCPMC12263372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.